|
IntelligentMDx appoints Richard Whitley, M.D. as an advisor
IntelligentMDx announced the appointment of Richard Whitley, M.D. as an advisor to the company. Dr. Whitley will advise the company on matters related to molecular diagnostic test development, clinical testing, and general clinical application of IntelligentMDx developed diagnostic tests. Previously, Dr. Whitley has been in collaboration with IntelligentMDx and has presented evaluations of IntelligentMDx diagnostic tests. “We are excited to welcome Dr. Whitley as an advisor to IntelligentMDx. We believe Dr. Whitley will be an excellent advisor on clinical matters and will help IntelligentMDx focus it’s proprietary molecular test development platform to areas of highest clinical relevance,” said Alice Jacobs, M.D., Chairman and CEO of IntelligentMDx.
Dr. Whitley is a world renowned clinical expert in infectious disease and holds a number of leadership service titles at the University of Alabama at Birmingham, including Distinguished Professor and Vice-Chair of the Department of Pediatrics, Director of the Division of Pediatric Infectious Diseases and Loeb Scholar in Pediatrics. Additionally, Dr. Whitley sits on the board of Gilead Sciences, is the Chair of the Board of Scientific Councilors for the National Center for Infectious Diseases of the U.S. Centers for Disease Control and Prevention (CDCP), and is Vice President of the Board of the Infectious Disease Society of America.
About IntelligentMDx
IntelligentMDx’s mission is to make FDA approved diagnostic kits. To guarantee quality for customers and partners, we design, develop and manufacture tests under FDA Quality System Regulations and ISO 13485:2003 guidelines. These tests have been, and will be, designed to run on a broad range of molecular systems for clinical diagnostics, drug development and applied sciences.
IntelligentMDx designs, develops and commercializes clinically impactful molecular diagnostic tests. Our goal is to support clinicians in their efforts to provide care with certainty. Our commercial offerings include emerging and re-emerging infectious threats and are available for use in CLIA laboratories covering the rapidly growing markets for transplant and health care-associated infections. IntelligentMDx’s expertise spans evolutionary biology, bioinformatics, and wet lab/molecular biology capabilities, harnessed by our proprietary product development process allowing for the rapid design and development of tests to meet clinical needs.
Media Contact:
For more information on IntelligentMDx, visit www.IntelligentMDx.com or contact Corporate Communications at cc@IntelligentMDx.com, 617-871-6400.
|